+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone

Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone

Seminars in Oncology 30(2): 265-269

To evaluate the activity of thalidomide in Waldenstrom's macroglobulinemia (WM), 20 patients were treated on a dose schedule that escalated from 200 mg/d to 600 mg/d. On an intention-to-treat basis, five (25%) patients achieved a partial response, which was noted within 3 months of treatment. Adverse effects were common and prevented dose escalation of thalidomide in 75% of patients and led to premature discontinuation of treatment in 35%. We subsequently evaluated the oral combination of clarithromycin (500 mg twice per day), low-dose thalidomide (200 mg once daily), and dexamethasone (40 mg once per week). Our preliminary analysis on 12 previously treated patients indicate activity of this regimen in WM: three patients achieved a partial response and two patients demonstrated monoclonal protein reduction of greater than 25%. This combination was associated with a variety of side effects due not only to thalidomide, but also to corticosteroids and to clarithromycin. Our preliminary data indicate that this combination may be a useful salvage regimen for some patients with heavily pretreated macroglobulinemia.

(PDF emailed within 0-6 h: $19.90)

Accession: 035980649

Download citation: RISBibTeXText

PMID: 12720150

DOI: 10.1053/sonc.2003.50079

Related references

Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. Seminars in Oncology 30(2): 270-274, 2003

BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemia. Leukemia & Lymphoma 43(9): 1777-1782, 2003

Clarithromycin, Thalidomide and Dexamethasone for the Treatment of Waldenstroms Macroglobulinemia. Blood 100(11): Abstract No 5099, November 16, 2002

Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation The MMVAR/IFM 25-4 Randomi. 2012

Treatment of Waldenstrom's macroglobulinemia with thalidomide. Journal of Clinical Oncology 19(16): 3596-3601, 2001

Successful treatment with rituximab and thalidomide of POEMS syndrome associated with Waldenstrom macroglobulinemia. Journal of the Neurological Sciences 297(1-2): 101-104, 2010

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology 30(20): 2475-2482, 2012

Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin. Acta Haematologica 137(3): 123-131, 2017

Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 112(12): 4452-4457, 2008

Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience. International Journal of Hematology 89(1): 34-38, 2009

Correlation of Thrombotic/Embolic Events with Features of Hypercoagulability in Previously Untreated Patients before and after Treatment with Thalidomide or Thalidomide-Dexamethasone. Blood 100(11): Abstract No 787, November 16, 2002

Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma. European Journal of Haematology 78(4): 297-302, 2007

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus doxorubicin and dexamethasone as induction therapy in previously untreated multiple myeloma patients. Acta Haematologica 129(1): 35-39, 2013

Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study. Cancer ChemoTherapy and Pharmacology 79(6): 1141-1149, 2017

Correlation of Peripheral Blood Plasma Levels of Angiogenesis Factors with Treatment of Thalidomide or Thalidomide - Dexamethasone in Prevoiusly Untreated Patients with Multiple Myeloma. Blood 100(11): Abstract No 3193, November 16, 2002